Lunai Bioworks Expects Nasdaq Trading Suspension on October 30
Bitget2026/10/22 23:00Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Lunai Bioworks’ Nasdaq-listed common stock is expected to be suspended from trading at the opening of business on October 30, 2026.
- Nasdaq’s October 21, 2026, delisting determination cited noncompliance with its $2.5 million minimum stockholders’ equity requirement.
- The company reported a $9.02 million stockholders’ deficit for the fiscal year ended June 30, 2026.
- It will not seek a hearing; voluntary delisting is expected to take effect on or about November 12, 2026.
- No over-the-counter quotation is planned, leaving the common stock without an assured trading market following the suspension.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610221900PR_NEWS_USPR_____LA79456) on October 22, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
FXStreet•2026/10/30 08:00

Fidelity's Timmer Warns Rising Rates Can Hurt Stocks Unless Earnings Keep Pace
BeInCrypto•2026/10/30 07:57
Hackers Target Crypto Users With Fake ChatGPT and Claude Apps
UToday•2026/10/30 07:42
Sanofi (SNY.US) Q3 profit far exceeds expectations as strong Dupixent demand cannot offset looming patent cliff concerns
Sanofi has raised its full-year sales and profit forecasts for the second consecutive quarter.
智通财经•2026/10/30 07:41
Crypto prices
MoreBitcoin
BTC
$77,940.44
-2.30%
Ethereum
ETH
$2,229.16
-3.29%
Tether USDt
USDT
$0.9984
-0.04%
BNB
BNB
$708.29
-5.44%
XRP
XRP
$1.25
-3.05%
USDC
USDC
$0.9996
-0.02%
Solana
SOL
$97.04
-2.64%
TRON
TRX
$0.3365
+1.67%
Hyperliquid
HYPE
$91.05
+15.75%
Zcash
ZEC
$1,245.83
+0.69%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now